Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
The Affiliated People's Hospital of Ningbo University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06520163CT.gov Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma | — | Recruiting | — | — | — |
NCT03458260CT.gov Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03091933CT.gov Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | — | Unknown | — | — | — |
NCT02703272CT.gov A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT02393157CT.gov Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | — | Recruiting | — | — | — |
NCT02408042CT.gov Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | — | Withdrawn | — | — | — |
NCT02371161CT.gov Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy | — | Unknown | — | — | — |
NCT01097057CT.gov Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells | — | Completed | — | — | — |
NCT00809341CT.gov R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00712582CT.gov Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma | — | Completed | — | — | — |
Show 10 more trialsShow fewer
NCT01148173CT.gov High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas | — | Unknown | — | — | — |
NCT00529503CT.gov A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | — | Terminated | — | — | — |
NCT00504751CT.gov Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL | — | Completed | — | — | — |
NCT01300793CT.gov Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide | — | Terminated | — | — | — |
NCT00324467CT.gov Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | — | Unknown | — | — | — |
NCT00126191CT.gov Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | — | Terminated | — | — | — |
NCT00088530CT.gov BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | — | Completed | — | — | — |
NCT00193505CT.gov Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma | — | Completed | — | — | — |
NCT00163761CT.gov Efficacy Study of Outpatient Therapy for Lymphoma | — | Completed | — | — | — |
NCT00187070CT.gov Large Cell Lymphoma Pilot Study III | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isocyclophosphamide (this asset) | The Affiliated People's Hospital of Ningbo University | P3 | BB · 66 |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BBB |
| Entecavir | Fudan University | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for Isocyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Angioimmunoblastic T-Cell Lymphoma | — | P4 | BBB · 76 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Isocyclophosphamide in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/isocyclophosphamide-non-hodgkin-lymphoma-108330
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →